Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders
March 09 2018 - 8:00AM
Issuance of U.S. Patent No. 9,895,301
Further Bolsters Aclaris’ Intellectual Patent
Portfolio
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that the United States Patent and Trademark Office
(USPTO) has issued U.S. Patent No. 9,895,301, which is directed to
methods related to the use and administration of a certain janus
kinase (JAK) inhibitor for treating hair loss disorders.
U.S. Patent No. 9,895,301 covers the use of
tofacitinib for inducing hair growth and for treating hair loss
disorders such as alopecia areata and androgenetic alopecia (AGA),
otherwise known as male/female pattern hair loss.
Additional issued claims pertain to methods of using
tofacitinib to treat particular phenotypes of alopecia areata, as
well as to treat other hair loss disorders. The ‘301 Patent
contains 67 claims and expires in November 2031.
This newly allowed patent is owned by The Trustees
of Columbia University in the City of New York and exclusively
licensed to Aclaris and is the latest U.S. patent to issue in
connection with Aclaris' JAK drug development program for
hair loss disorders.
“We are extremely pleased with the continued
development of the patent portfolio we exclusively licensed from
Columbia. This new issuance continues to expand the breadth
and depth of our JAK inhibitor intellectual property portfolio
covering methods of use for certain JAK inhibitors for the
treatment of hair loss disorders. The issuance of this patent is
another step in the development of a robust patent portfolio
relating to JAK inhibition and hair loss,” said Dr. Neal Walker,
President and Chief Executive Officer of Aclaris.
Aclaris has exclusively licensed several patents
and patent applications involving novel selective JAK 1/3
inhibitors, including a patent portfolio that covers Aclaris’
product candidates ATI-501 (formerly ATI-50001) and ATI-502
(formerly ATI-50002), which are oral and topical formulations,
respectively, also being developed as potential treatments for
alopecia areata. In addition, Aclaris has exclusively
licensed a patent portfolio from Columbia University directed to
methods of using JAK inhibitors for the treatment of alopecia
areata, AGA, and other dermatological conditions. This
portfolio includes the recently issued U.S. patent discussed above,
as well as issued U.S. patents directed to methods of treating
alopecia areata, AGA and other hair loss disorders by administering
ruxolitinib, baricitinib, or decernotinib, and issued patent claims
in Japan directed to pharmaceutical compositions comprising
ruxolitinib, baricitinib, tofacitinib or other JAK inhibitors for
use in treating alopecia areata, AGA and other hair loss
disorders.
About Aclaris Therapeutics,
Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company committed to identifying, developing and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunodermatology.
Aclaris is focused on market segments with no FDA-approved
medications or where treatment gaps exist. Aclaris is based in
Wayne, Pennsylvania. More information can be found by visiting the
Aclaris website at www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that
do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by words such as “believe”, “expect”, “may”, “plan,” “potential,”
“will,” and similar expressions, and are based on Aclaris’ current
beliefs and expectations. These forward-looking statements include
expectations regarding the development of Aclaris’ product
candidates focused on JAK inhibition for the treatment of hair loss
disorders, including Aclaris’ intellectual property strategy. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Aclaris’ reliance on third parties over which
it may not always have full control, risks associated with
maintaining its intellectual property portfolio and other risks and
uncertainties that are described in Aclaris’ Annual Report on Form
10-K for the year ended December 31, 2016, Aclaris’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2017, and
other filings Aclaris makes with the SEC from time to time. These
documents are available under the “Financial Information” section
of the Investors page of Aclaris’ website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aclaris Contact Michael Tung, M.D. Senior Vice President
Corporate Strategy/Investor Relations 484-329-2140
mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024